ClinicalTrials.gg
CompletedNCT05743907Updated Mar 14, 2025

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

A Phase 4 interventional study of DA-2811 and Forxiga in Diabetes Mellitus, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Dong-A ST Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 224 studies in Diabetes Mellitus with a site in Korea, Republic of — 22 open to participants now, 25 under way, 3 of them phase 3. Diabetes Mellitus · Korea, Republic of.

Enrollment
75th of 181
231 · median 140
Started
2023
with 6 others
Phase 4
48 of 224
4 open now
Registered
191st of 224
by date

Among the 224 studies in Diabetes Mellitus with a site in Korea, Republic of, this one is the 75th largest by enrollment of the 181 interventional ones that give a count, is one of 7 that started in 2023, is one of 48 in phase 4, and was the 191st registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

22 of the 224 studies in Diabetes Mellitus with a site in Korea, Republic of are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Diabetes Mellitus with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with 7.0%≤≤10.0% at screening
  • Subjects treated with 1,000mg/day or higher dose of metformin for at least 8 weeks prior to screening
  • Subjects with 18.5kg/m2≤≤40kg/m2 at screening
  • Subject who is willing and able to provide indicating that they understand the purpose and procedures required for the study

Exclusion criteria

Exclusion Criteria:

  • Subjects with fasting plasma glucose≥240mg/dL at screening
  • Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
  • Subject with and AST 3 times or higher than upper normal range
  • Subject with history of myocardial infarction, cerebral infarction within 3 months prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    DA-2811

    DA-2811 + Forxiga placebo

    Drug: DA-2811

  • Active comparator
    Forxiga

    Forxiga + DA-2811 placebo

    Drug: Forxiga

Interventions

  • DA-2811 Group: DA-2811 + Forxiga placebo

  • Forxiga Group: Forxiga + DA-2811 placebo

06

What researchers measure

Primary outcomes

  1. HbA1c(%)

    Time frame: Change from baseline at 24 weeks

07

Study locations

1 site
  • The Catholic University of Korea Bucheon St. Mary's Hospital
    Bucheon, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Mar 2025, 22 months.

Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 22 months is above that.

Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Feb 24, 2023
StartActual
Apr 25, 2023
Primary completionActual
Mar 10, 2025
CompletionActual
Mar 10, 2025
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743907
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Apr 25, 2023
Primary completion
Mar 10, 2025
Completion
Mar 10, 2025
Last update
Mar 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DA-2811

Start the discussion